Yujie Wei

Dr. Yujie Wei


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
CQCaihao Qu
Caihao Qu
XYXin YAN
Xin YAN
YWYujie Wei
Yujie Wei
FTFutian Tang
Futian Tang
YLYumin Li
Yumin Li
CD8+ T lymphocytes are critical in the immune response against neoplasms, yet the prognostic relevance of CD8+ T cell-associated genes in hepatocellular carcinoma (HCC) is not fully understood. We sourced single-cell RNA-sequencing (scRNA-seq) and bulk RNA-seq data for HCC from the GSE98638 dataset and The Cancer Genome Atlas (TCGA) repository. We utilized Weighted Gene Correlation Network Analysis (WGCNA) to identify CD8+ T cell-related genes. A clinical prognostic model for risk stratification was then constructed via Cox-Lasso regression analysis. The Immunophenotypic Score (IPS) was utilized to evaluate the potential of immunotherapeutic interventions in the categorized cohorts. Validation of the expression of CD8+ T cell-associated risk genes was performed using quantitative reverse transcription PCR (qRT-PCR). Integrating scRNA-seq with RNA-seq data, we identified five CD8+ T cell-related signature genes: IKBKE, ATP1B3, MSC, ADA, and BATF. Notably, HCC patients in the high-risk group had markedly decreased overall survival. Elevated infiltration levels of CD8+ T cells, B cells, and macrophages were observed in the high-risk group. Moreover, there was a positive correlation between the risk score and immune checkpoints (ICPs), including PDCD1, CD274, and CTLA4. Patients within the high-risk group subject to PD1 and CTLA4 blockade exhibited higher IPS levels. Additionally, the expression of the five risk genes was upregulated in HCC cell lines and tissues compared to normal cells and tissues. Our findings establish a prognostic signature based on CD8+ T cells, offering a potent predictive model for clinical outcomes and responsiveness to immunotherapy in HCC patients.

24 April 2024 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
XZXiaoxia Zhang
Xiaoxia Zhang
YWYujie Wei
Yujie Wei
FWFanqi Wu
Fanqi Wu
MLMei Li
Mei Li
CHCong Han
Cong Han
YLYumin Li
Yumin Li
Purpose: Gastric cancer (GC) is prevalent as one of the most common malignant tumors globally, with a particularly high incidence in China. The role of UBE2L3 in the initiation and progression of various cancers has been well documented, but its specific significance in GC is not yet fully elucidated. The objective of this study is to examine the expression and importance of UBE2L3 in human gastric cancer tissues. Methods: Immunohistochemical staining and survival analysis were conducted on 125 cases of GC. Western blot and quantitative real-time polymerase chain reaction (qRT-PCR) were employed to assess the expression of UBE2L3 in GC cell lines. Cell lines with UBE2L3 knockdown and overexpression were cultured through lentivirus transfection and subsequently assessed using Western blot analysis. The involvement of UBE2L3 in the proliferation, invasion, and apoptosis of GC cells was confirmed through in vitro experiments, and its capacity to facilitate tumor growth was also validated in in vivo studies. Results: The up-regulation of UBE2L3 expression was observed in GC, and its high expression was found to be significantly associated with the degree of differentiation (χ2 = 6.153, P = 0.0131), TNM stage (χ2 = 6.216, P = 0.0447), and poor overall survival. In vitro, UBE2L3 has been shown to enhance functions in GC cell lines, such as promoting proliferation and invasion, and inhibiting apoptosis. In vivo experiments have validated the role of UBE2L3 in promoting tumor growth. Conclusions: The findings of our study demonstrate the significant involvement of UBE2L3 in the pathogenesis and advancement of gastric cancer, suggesting its potential as a therapeutic target.

22 September 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
SCSijing Chen
Sijing Chen
YZYunyang Zhao
Yunyang Zhao
YPYunqi Pan
Yunqi Pan
ZZZhihui Zhao
Zhihui Zhao
ZMZhonghua Ma
Zhonghua Ma
FTFutian Tang
Futian Tang
Background/Objectives: Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality worldwide, and current targeted therapeutic options remain inadequate. Gilteritinib, a clinically approved tyrosine kinase inhibitor, has shown antitumor activity in hematologic malignancies; however, its therapeutic role and underlying mechanisms in HCC remain unclear. Methods: The effects of gilteritinib on HCC were evaluated in Hepa1-6 and Huh-7 cells. Cell proliferation, migration, invasion, apoptosis, and cell cycle distribution were assessed by CCK-8, wound healing, Transwell, and flow cytometry assays. Protein expression and total calpain activity were assessed by Western blotting and enzymatic activity assays. Surface plasmon resonance (SPR) analysis was used to examine the cellular association of gilteritinib with HCC cells. Antitumor efficacy and safety were further evaluated in a Hepa1-6 allograft mouse model. Results: Gilteritinib significantly inhibited the proliferation, migration, and invasion of HCC cells and induced G2/M-phase arrest and apoptosis. Gilteritinib treatment was associated with reduced calpain-1 expression and total calpain activity. These changes were accompanied by decreased phosphorylation of STAT3 and AKT, downregulation of Bcl-2, and upregulation of Bax. In vivo, gilteritinib markedly suppressed tumor growth in Hepa1-6 tumor-bearing mice. Conclusions: Collectively, gilteritinib exerts antitumor effects against HCC both in vitro and in vivo, and these effects are closely associated with reduced calpain-1 expression and inhibition of STAT3/AKT signaling. These findings suggest that gilteritinib has therapeutic potential in HCC and highlight calpain-1 as a candidate downstream correlate worthy of further mechanistic study.